WALTHAM, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2013. Total revenues for the third quarter of 2013 were $21.6 million, of which $19.3 million were U.S. net Feraheme® (ferumoxytol) sales, the highest Feraheme quarterly sales since launch in 2009. AMAG generated positive cash flows during the quarter and ended the third quarter with $213.5 million in cash and investments.
Help employers find you! Check out all the jobs and post your resume.
